Guangxi Wuzhou Zhongheng Group Co.,Ltd

600252

CNE0000015F9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-16 EDT			5-day change	1st Jan Change
2.23 ^CNY	-0.89%		-2.62%	-11.16%

06-05	Zhongheng Group Secures Drug Registration Certificate for New Respiratory Drug	MT
04-29	Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Guangxi Wuzhou Zhongheng Proposes Jiang Chenghou as Duty of Chair of Directorate

February 03, 2016 at 07:56 am

Guangxi Wuzhou Zhongheng announced the 24th session of 7th directorate meeting held on February 1, 2016 has approved the proposal of recommending Director Jiang Chenghou to Perform Duty of Chair of Directorate.

Latest news about Guangxi Wuzhou Zhongheng Group Co.,Ltd

Zhongheng Group Secures Drug Registration Certificate for New Respiratory Drug	06-05	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd commences an Equity Buyback for CNY 200 million worth of its shares, under the authorization approved on March 28, 2024.	04-16	CI
Guangxi Honggui Capital Operation Group Co.,Ltd. agreed to acquire 18% stake in Guangxi United Asset Management Co., Ltd from Guangxi Wuzhou Zhongheng Group Co.,Ltd for approximately CNY 190 million.	04-08	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug	03-18	MT
Wuzhou Zhongheng’s Drug For Preventing Chemotherapy-Related Nausea Passes Consistency Test	11-10	MT
Sealand Securities Co., Ltd. announced that it has received CNY 3.192189985 billion in funding from a group of investors	11-09	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) added to S&P Global BMI Index	23-09-18	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) added to FTSE All-World Index	23-09-18	CI
Wuzhou Zhongheng Gets Nod to Trial Ovarian Cancer Drug	23-09-15	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Guangxi Wuzhou Zhongheng Receives 42 Million Yuan in Government Subsidy	23-08-17	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Restrictions on Guangxi Wuzhou Zhongheng Drugs in 2022 Chinese Drug Catalogue Amended	23-01-24	MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) dropped from S&P Global BMI Index	22-06-20	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) dropped from FTSE All-World Index	22-06-13	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-17	CI
Beibu Gulf Property & Casualty Insurance Co.,Ltd. announced that it expects to receive CNY 450 million in funding from Guangxi Wuzhou Zhongheng Group Co.,Ltd	21-11-21	CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI

Chart Guangxi Wuzhou Zhongheng Group Co.,Ltd

Duration

Period

Chart Guangxi Wuzhou Zhongheng Group Co.,Ltd

More charts

Company Profile

GUANGXI WUZHOU ZHONGHENG GROUP CO., LTD is a China-based company, principally engaged in the manufacture of pharmaceuticals and food production. The Company's pharmaceuticals include cardiovascular drugs, medicine for bruises, gynecology medication and other general drugs. The Company also provides Chinese herbal jelly products, Chinese herbal beverages and others. The Company is also engaged in the development of real estate, including the development and sales of commercial housings and stores. The Company mainly conducts its businesses within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUANGXI WUZHOU ZHONGHENG GROUP CO.,LTD	-11.16%	1.07B
ELI LILLY AND COMPANY	+52.33%	791B
NOVO NORDISK A/S	+40.45%	630B
MERCK & CO., INC.	+17.09%	328B
ABBVIE INC.	+9.23%	298B
ASTRAZENECA PLC	+17.25%	246B
ROCHE HOLDING AG	+0.41%	225B
NOVARTIS AG	+10.22%	218B
AMGEN INC.	+5.01%	160B
PFIZER, INC.	-6.32%	156B